G protein-coupled receptors (GPCRs) modulate cellular signaling, often in a ligand-specific manner. Cellular effects regulated include differentiation, proliferation, hormonal regulation, and neuronal activity. Further, they are involved in many disease-relevant processes, such as cancer and neurodevelopmental diseases, and represent the largest class of drug targets. Therefore, monitoring how GPCRs are regulated in their activity is crucial to understand their role in physiological processes and implications for drug development. Split TEV, a method based on TEV protease fragment complementation, can be used to sensitively assay GPCR activities in living cells. The activity of a given GPCR is monitored through its binding to β-arrestin. Split TEV reporters provide at minimum a two-step amplification process facilitating a flexible format and a robust readout. For the initial setup, a GPCR of interest and β-arrestin are fused to the N- and C-terminal fragments of the TEV protease, and occurred interactions are indicated by increased fluorescence or luminescence of TEV cleavage-dependent reporters. The experimental procedure takes 24–72 h to complete, depending on the cell type and complexity of the experimental setup applied.
GPCR β-Arrestin Split TEV Protein-protein interaction Dose-response assay Compound profiling
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
This work was supported by the Max Planck Society and the BMBF grant VIP005.
Hamdan FF, Audet M, Garneau P et al (2005) High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 10:463–475. doi:10.1177/1087057105275344PubMedCrossRefGoogle Scholar
Yan Y-X, Boldt-Houle DM, Tillotson BP et al (2002) Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology. J Biomol Screen 7:451–459. doi:10.1177/108705702237677PubMedCrossRefGoogle Scholar
Zhao X, Jones A, Olson KR et al (2008) A homogeneous enzyme fragment complementation-based beta-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors. J Biomol Screen 13:737–747. doi:10.1177/1087057108321531PubMedCrossRefGoogle Scholar
Michnick SW, Ear PH, Manderson EN et al (2007) Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat Rev Drug Discov 6:569–582. doi:10.1038/nrd2311PubMedCrossRefGoogle Scholar
Kapust RB, Tözsér J, Fox JD et al (2001) Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng 14:993–1000PubMedCrossRefGoogle Scholar